Serial Number 98420825
731

Registration Progress

Application Filed
Feb 26, 2024
Under Examination
Jul 9, 2024
Approved for Publication
May 14, 2024
Published for Opposition
May 14, 2024
Registered

Attorney Assistance

Statement of Use Due - Extension 2 Granted
Due: Jan 09, 2026 161 days

Trademark Image

Basic Information

Serial Number
98420825
Filing Date
February 26, 2024
Published for Opposition
May 14, 2024
Drawing Code
2

Status Summary

Current Status
Active
Status Code
731
Status Date
Jul 7, 2025
Application
Pending
Classes
005

Rights Holder

Novartis AG

99
Address
CH-4002
Basel 4002
CH

Ownership History

Novartis AG

Original Applicant
99
Basel CH

Novartis AG

Owner at Publication
99
Basel CH

Legal Representation

Attorney
Maury M. Tepper, III

USPTO Deadlines

Next Deadline
161 days remaining
Statement of Use Due - Extension 2 Granted
Due Date
January 09, 2026
Extension Available
Until July 09, 2025

Application History

23 events
Date Code Type Description Documents
Jul 8, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 7, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 7, 2025 EXT2 S SOU EXTENSION 2 FILED Loading...
Jul 7, 2025 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jan 7, 2025 EXT1 S SOU EXTENSION 1 FILED Loading...
Jan 7, 2025 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jan 7, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 7, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 9, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
May 14, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
May 14, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 24, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Apr 8, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 1, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 1, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 1, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Mar 27, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Mar 27, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Mar 27, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Mar 20, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 20, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 20, 2024 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Feb 26, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Additional Information

Design Mark
The mark consists of thick outlines of two back-to-back ovals with the outside facing sides indented, all in the colors light blue and dark blue. The color white represents transparent areas and is not part of the mark.
Color Claim
The color(s) light blue and dark blue is/are claimed as a feature of the mark.

Classification

International Classes
005